JW Shinyak Corporation

A067290

KR7067290007

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
1,855 ^KRW	-0.22%		+0.82%	-25.20%

03-18	JW Shinyak Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	JW Shinyak Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

JW Shinyak Corporation announced that it has received KRW 25 billion in funding from a group of investors.

March 29, 2016

On March 30, 2016, JW Shinyak Corporation closed the transaction.

Latest news about JW Shinyak Corporation

JW Shinyak Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
JW Shinyak Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
JW Shinyak Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
JW Shinyak Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
JW Shinyak Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	16/03/23	CI
JW Shinyak Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
JW Shinyak Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI
JW Shinyak Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
JW Holdings Corporation agreed to acquire additional 5.55459% stake in JW Shinyak Corporation for KRW 11.6 billion.	27/04/22	CI
JW Shinyak Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	21/03/22	CI
JW Shinyak Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/11/21	CI
JW Shinyak Corporation cancelled the acquisition of an additional 28.9% stake in JW CreaGene Co., Ltd. from group of sellers for KRW 30.7 billion.	15/01/21	CI
JW Shinyak Corporation agreed to acquire an additional 28.9% stake in JW CreaGene Co., Ltd. from group of sellers for KRW 30.7 billion.	16/01/20	CI
JW Shinyak Corporation announced that it has received KRW 25 billion in funding	21/11/19	CI
JW Shinyak Corporation announced that it expects to receive KRW 25 billion in funding	20/11/19	CI
JW CreaGene Co., Ltd. announced that it has received KRW 25 billion in funding from JW Shinyak Corporation	09/02/17	CI
JW Shinyak Corporation announced that it has received KRW 25 billion in funding from a group of investors.	29/03/16	CI
JW Shinyak Corporation announced that it expects to receive KRW 25 billion in funding from a group of investors.	27/03/16	CI
JW Holdings Corporation cancelled the sale of 4.61% stake in JW Shinyak Corporation.	03/11/12	CI

JW SHINYAK CORPORATION is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals. The Companyâs main products portfolio consists of antibiotics, anesthetics, respiratory remedies, urology remedies, cardiovascular remedies, allergy remedies, digestive remedies, anti-inflammatory drugs, antivirals as well as acne remedies, among others. In addition, it also involves in the provision of cosmetics, such as creams, cleansers, toners, essences, lotions and others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
JW SHINYAK CORPORATION	-25.20%	69.5M
KYOWA KIRIN CO. LTD.	+10.23%	8.96B
SK BIOPHARMACEUTICALS CO., LTD.	-10.76%	5.19B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+51.58%	4.77B
YUHAN CORPORATION	+12.50%	4.26B
BETTA PHARMACEUTICALS CO., LTD.	-20.70%	2.37B
INDIVIOR PLC	+12.83%	2.3B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.65%	2.21B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+19.51%	2.17B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B